Assay Development Services

Assay development expertise

We have one of the most extensive routine and specialty testing menus in the industry and our technology partnerships and internal assay development programs have produced a large offering of novel biomarkers. Since 2015, we have validated >450 new assays including over 250 biomarker assays each year.  

Our global laboratories, including 3 satellite translational science laboratories, are equipped with industry-leading development expertise and value-added offerings. 

Our Translational Science Laboratories (TSL) focus on facilitating technology transfers from Sponsors, and developing and validating new assays with staff that are dedicated to the development of assays and validation. The TSL perform custom development and validation and re-validation of assays (fit-for-purpose or full extensive validation) and are committed to building strong and confident relationships between our scientists and customers.

We have recently collaborated with the University of Texas Medical Branch (UTMB) to develop a novel assay for COVID-19 (SARS-CoV-2) tests, to drive rapid development of a Coronavirus vaccine. Once a viable assay is developed, we will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine. Read more in our news release.

Meeting complex demands

Advancing our services

Constantly expanding menu of >3,500 tests and assays

For oncology drug development, our anatomic and molecular pathology, immunoassay and genomics-based assay development and testing, in conjunction with flow cytometry services provide a customized, end-to-end solution specifically suited for the unique combination of therapeutic indication and targeted mechanism-of-action.

Biomarker discovery and insights

Our biomarker discovery experts provide a better understanding of therapeutic targets, molecular signaling, drug biology and patient response. These insights can enable us to develop new assays for your trials.